Literature DB >> 9160251

Prevention of motoneuron death by adenovirus-mediated neurotrophic factors.

M Giménez y Ribotta1, F Revah, L Pradier, I Loquet, J Mallet, A Privat.   

Abstract

Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease characterized by progressive loss of motoneurons, and has no effective treatment. Experimental studies in rodents have shown that motoneurons respond to a variety of molecules including brain-derived neurotrophic factor (BDNF). and the glial-cell line-derived neurotrophic factor (GDNF). Here we investigated the neuroprotective effect of these growth factors, encoded by an adenovirus, on the death of axotomized facial motoneurons in newborn rats. We used a new gene therapy strategy that involves gene transfer to motoneurons by intramuscular injection of an adenoviral vector, which is retrogradely transported from injected target muscle (Finiels et al.,: NeuroReport 7:373-378, 1995). A significant increased survival of motoneurons was observed in animals pretreated with adenovirus encoding BDNF (34.5%, P < 0.05) ou GDNF (41.9%, P < 0.05) 1 week after axotomy. These results indicate that pretreatment with BDNF or GDNF, using this therapeutic strategy, is able to prevent the massive death of motoneurons that normally follows axotomy in the neonatal period, opening new perspectives to limit neuronal death in degenerative disorders.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9160251     DOI: 10.1002/(sici)1097-4547(19970501)48:3<281::aid-jnr11>3.3.co;2-i

Source DB:  PubMed          Journal:  J Neurosci Res        ISSN: 0360-4012            Impact factor:   4.164


  21 in total

Review 1.  How to improve the diagnostic process.

Authors:  A Eisen
Journal:  J Neurol       Date:  1999-11       Impact factor: 4.849

Review 2.  Treatment of amyotrophic lateral sclerosis.

Authors:  A Eisen; M Weber
Journal:  Drugs Aging       Date:  1999-03       Impact factor: 3.923

3.  A transgenic mouse model engineered to investigate human brain-derived neurotrophic factor in vivo.

Authors:  Fabrice Guillemot; Italina Cerutti; Charles Auffray; Marie-Dominique Devignes
Journal:  Transgenic Res       Date:  2007-01-16       Impact factor: 2.788

4.  Complete and long-term rescue of lesioned adult motoneurons by lentiviral-mediated expression of glial cell line-derived neurotrophic factor in the facial nucleus.

Authors:  A F Hottinger; M Azzouz; N Déglon; P Aebischer; A D Zurn
Journal:  J Neurosci       Date:  2000-08-01       Impact factor: 6.167

5.  Intramuscular scAAV9-SMN injection mediates widespread gene delivery to the spinal cord and decreases disease severity in SMA mice.

Authors:  Sofia Benkhelifa-Ziyyat; Aurore Besse; Marianne Roda; Sandra Duque; Stéphanie Astord; Romain Carcenac; Thibaut Marais; Martine Barkats
Journal:  Mol Ther       Date:  2013-01-08       Impact factor: 11.454

6.  GDNF: a novel factor with therapeutic potential for neurodegenerative disorders.

Authors:  K M Walton
Journal:  Mol Neurobiol       Date:  1999-02       Impact factor: 5.590

7.  Adenoviral cardiotrophin-1 gene transfer protects pmn mice from progressive motor neuronopathy.

Authors:  T Bordet; H Schmalbruch; B Pettmann; A Hagege; L Castelnau-Ptakhine; A Kahn; G Haase
Journal:  J Clin Invest       Date:  1999-10       Impact factor: 14.808

Review 8.  Glutamate and neurotrophic factors in neuronal plasticity and disease.

Authors:  Mark P Mattson
Journal:  Ann N Y Acad Sci       Date:  2008-11       Impact factor: 5.691

9.  Neurotrophic growth factors for the treatment of amyotrophic lateral sclerosis: where do we stand?

Authors:  Alexandre Henriques; Claudia Pitzer; Armin Schneider
Journal:  Front Neurosci       Date:  2010-06-11       Impact factor: 4.677

Review 10.  Potential new complication in drug therapy development for amyotrophic lateral sclerosis.

Authors:  Svitlana Garbuzova-Davis; Avery Thomson; Crupa Kurien; R Douglas Shytle; Paul R Sanberg
Journal:  Expert Rev Neurother       Date:  2016-07-15       Impact factor: 4.618

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.